NO20055730D0 - Forbedret produksjon av rosuvastatin kalsiumsalt - Google Patents

Forbedret produksjon av rosuvastatin kalsiumsalt

Info

Publication number: NO20055730D0
Authority: NO; Norway
Prior art keywords: calcium salt; improved production; rosuvastatin calcium; rosuvastatin; production
Prior art date: 2003-06-05

Application number

NO20055730A

Other languages

English (en)

Other versions

NO332971B1 (no

NO20055730L (no

Inventor

Nigel Phillip Taylor

John Horbury

Jeffrey Norman Crabb

Original Assignee

Astrazeneca Uk Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-05

Filing date

2005-12-05

Publication date

2005-12-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33512687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20055730(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-12-05 Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd

2005-12-05 Publication of NO20055730D0 publication Critical patent/NO20055730D0/no

2005-12-27 Publication of NO20055730L publication Critical patent/NO20055730L/no

2013-02-11 Publication of NO332971B1 publication Critical patent/NO332971B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20055730A 2003-06-05 2005-12-05 Forbedret produksjon av rosuvastatin kalsiumsalt NO332971B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB0312896.4A GB0312896D0 (en)	2003-06-05	2003-06-05	Chemical process
GBGB0324793.9A GB0324793D0 (en)	2003-06-05	2003-10-24	Chemical process
PCT/GB2004/002373 WO2004108691A1 (en)	2003-06-05	2004-06-03	Improved production of rosuvastatin calcium salt

Publications (3)

Publication Number	Publication Date
NO20055730D0 true NO20055730D0 (no)	2005-12-05
NO20055730L NO20055730L (no)	2005-12-27
NO332971B1 NO332971B1 (no)	2013-02-11

Family

ID=33512687

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20055730A NO332971B1 (no)	2003-06-05	2005-12-05	Forbedret produksjon av rosuvastatin kalsiumsalt

Country Status (25)

Country	Link
US (1)	US8063213B2 (no)
EP (1)	EP1633727B1 (no)
JP (1)	JP4651615B2 (no)
KR (1)	KR101099934B1 (no)
CN (1)	CN100422157C (no)
AR (1)	AR044773A1 (no)
AT (1)	ATE464297T1 (no)
AU (1)	AU2004245291B2 (no)
BR (1)	BRPI0410922B8 (no)
CA (1)	CA2527314C (no)
CO (1)	CO5640116A2 (no)
DE (1)	DE602004026576D1 (no)
ES (1)	ES2341858T3 (no)
GB (2)	GB0312896D0 (no)
IL (1)	IL172075A (no)
IS (1)	IS2751B (no)
MX (1)	MXPA05013128A (no)
MY (1)	MY140820A (no)
NO (1)	NO332971B1 (no)
NZ (1)	NZ543962A (no)
RU (1)	RU2361864C2 (no)
SA (1)	SA04250223B1 (no)
TW (1)	TWI341310B (no)
UY (1)	UY28341A1 (no)
WO (1)	WO2004108691A1 (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0003305D0 (en)	2000-02-15	2000-04-05	Zeneca Ltd	Pyrimidine derivatives
GB0011120D0 (en)	2000-05-09	2000-06-28	Avecia Ltd	Process
NL1015744C2 (nl)	2000-07-19	2002-01-22	Dsm Nv	Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
AU2002318041B2 (en)	2001-07-13	2008-01-03	Astrazeneca Uk Limited	Preparation of aminopyrimidine compounds
EP1323717A1 (en)	2001-12-27	2003-07-02	Dsm N.V.	Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
EP1375493A1 (en)	2002-06-17	2004-01-02	Dsm N.V.	Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en)	2002-08-13	2002-09-18	Astrazeneca Ab	Chemical process
MXPA05006425A (es)	2002-12-16	2005-08-19	Astrazeneka Uk Ltd	Procedimiento para la preparacion de compuestos de pirimidina.
GB0312896D0 (en)	2003-06-05	2003-07-09	Astrazeneca Ab	Chemical process
UY28501A1 (es) *	2003-09-10	2005-04-29	Astrazeneca Uk Ltd	Compuestos químicos
GB0322552D0 (en)	2003-09-26	2003-10-29	Astrazeneca Uk Ltd	Therapeutic treatment
GB0324791D0 (en) *	2003-10-24	2003-11-26	Astrazeneca Ab	Chemical process
US7851624B2 (en)	2003-12-24	2010-12-14	Teva Pharamaceutical Industries Ltd.	Triol form of rosuvastatin and synthesis of rosuvastatin
WO2005077917A1 (en) *	2004-01-19	2005-08-25	Ranbaxy Laboratories Limited	Amorphous salts of rosuvastatin
GB0428328D0 (en)	2004-12-24	2005-02-02	Astrazeneca Uk Ltd	Chemical process
CA2683975A1 (en) *	2005-02-22	2006-08-31	Teva Pharmaceutical Industries Ltd.	Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
WO2006136408A2 (en)	2005-06-24	2006-12-28	Lek Pharmaceuticals D.D.	Process for preparing pure amorphous rosuvastatin calcium
CZ299215B6 (cs) *	2005-06-29	2008-05-21	Zentiva, A. S.	Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny
GB0514078D0 (en) *	2005-07-08	2005-08-17	Astrazeneca Uk Ltd	Chemical process
BRPI0605918A2 (pt) *	2005-08-16	2009-05-26	Teva Pharma	rosuvastatina cálcica com um baixo conteúdo de sal
EP1805148A2 (en)	2005-08-16	2007-07-11	Teva Pharmaceutical Industries Ltd.	Crystalline rosuvastatin intermediate
HU227696B1 (en) *	2006-04-13	2011-12-28	Egyt Gyogyszervegyeszeti Gyar	Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
HUE027872T2 (en)	2006-05-03	2016-11-28	Msn Laboratories Private Ltd	A novel process for statins and their pharmaceutically acceptable salts
HUE028475T2 (en)	2006-10-09	2016-12-28	Msn Laboratories Private Ltd	A novel process for the preparation of statins and their pharmaceutically acceptable salts
TW200831469A (en) *	2006-12-01	2008-08-01	Astrazeneca Uk Ltd	Chemical process
HU230981B1 (hu) *	2007-10-12	2019-08-28	Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság	Eljárás rosuvastatin só előállítására
WO2009143776A1 (zh)	2008-05-27	2009-12-03	常州制药厂有限公司	瑞舒伐他汀钙盐的制备方法及其中间体
EP2138165A1 (en)	2008-06-27	2009-12-30	KRKA, tovarna zdravil, d.d., Novo mesto	Pharmaceutical composition comprising a statin
EA024554B1 (ru)	2008-06-27	2016-09-30	Крка, Товарна Здравил, Д.Д., Ново Место	Твердая лекарственная форма, содержащая розувастатин, и способ ее получения
CN102186843A (zh) *	2008-09-09	2011-09-14	拜康有限公司	用于制备瑞舒伐他汀缩丙酮钙的方法
EP2327682A1 (en)	2009-10-29	2011-06-01	KRKA, D.D., Novo Mesto	Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
SI2373609T1 (sl)	2008-12-19	2013-12-31	Krka, D.D., Novo Mesto	Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov
EP2387561A4 (en)	2009-01-19	2012-07-25	Msn Lab Ltd	IMPROVED PROCESS FOR THE PREPARATION OF HIGH-PURITY (3R, 5S) -7-β-CYCLOPROPYL-4- (4-FLUOROPHENYL) QUINOLIN-3-YL-3,5-DIHYDROXY-6 (E) -HEPTENOIC ACID, INCLUDING ITS PHARMACEUTICALLY ACCEPTABLE SALTS
US8987444B2 (en)	2010-01-18	2015-03-24	Msn Laboratories Private Limited	Process for the preparation of amide intermediates and their use thereof
EP2560970A1 (en)	2010-04-23	2013-02-27	Ranbaxy Laboratories Limited	NOVEL INTERMEDIATES FOR THE PREPARATION OF HMG-CoA REDUCTASE INHIBITORS
WO2012011129A2 (en) *	2010-07-22	2012-01-26	Msn Laboratories Limited	Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt
CN105753834B (zh) *	2016-03-25	2018-08-21	河南师范大学	一种瑞舒伐他汀钙关键手性中间体的合成方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4645858A (en)	1982-03-22	1987-02-24	G. D. Searle & Co.	Pentanedioic acid derivatives
DE3741509A1 (de)	1987-12-08	1989-06-22	Hoechst Ag	Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
EP0367895A1 (en)	1988-10-06	1990-05-16	Sandoz Ag	Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
US5026698A (en)	1988-11-02	1991-06-25	Nissan Chemical Industries, Ltd.	Thienopyridine type mevalonolactones
JP2648897B2 (ja) *	1991-07-01	1997-09-03	塩野義製薬株式会社	ピリミジン誘導体
WO1993008823A1 (en)	1991-11-06	1993-05-13	Tanabe Seiyaku Co., Ltd.	Guanidinyl and related cell adhesion modulation compounds
US5278313A (en)	1992-03-27	1994-01-11	E. R. Squibb & Sons, Inc.	Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors
ES2106926T3 (es)	1992-07-02	1997-11-16	Hoechst Ag	Procedimiento para la preparacion del ester terc-butilico del acido (3r,5s)6-hidroxi-3,5-o-isopropiliden-3,5-dihidroxi-hexanoico.
EP1148049B1 (en)	1995-07-17	2004-12-15	Warner-Lambert Company	Crystalline R-(R,R)$-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl -1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
US6278001B1 (en)	1995-11-28	2001-08-21	L'oréal	Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
FR2741620B1 (fr)	1995-11-28	1997-12-26	Oreal	Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
WO1997049681A1 (en)	1996-06-24	1997-12-31	Astra Aktiebolag (Publ)	Polymorphic compounds
JP4440476B2 (ja)	1998-12-10	2010-03-24	株式会社カネカ	シンバスタチンの製造方法
GB9900339D0 (en) *	1999-01-09	1999-02-24	Zeneca Ltd	Chemical compounds
GB9903472D0 (en) *	1999-02-17	1999-04-07	Zeneca Ltd	Chemical process
WO2001022962A1 (en)	1999-09-30	2001-04-05	Merck & Co., Inc.	Anti-hypercholesterolemic drug combination
CN1423634A (zh)	1999-11-17	2003-06-11	特瓦制药工业有限公司	阿托伐他汀钙的多晶型物
GB0001621D0 (en)	2000-01-26	2000-03-15	Astrazeneca Ab	Pharmaceutical compositions
GB0003305D0 (en) *	2000-02-15	2000-04-05	Zeneca Ltd	Pyrimidine derivatives
WO2001072706A1 (en)	2000-03-28	2001-10-04	Biocon India Limited	Synthesis of [r-(r,r)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
GB0011120D0 (en) *	2000-05-09	2000-06-28	Avecia Ltd	Process
GB0011163D0 (en)	2000-05-10	2000-06-28	Astrazeneca Ab	Chemical compound
NL1015744C2 (nl) *	2000-07-19	2002-01-22	Dsm Nv	Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
WO2002030415A1 (en)	2000-10-05	2002-04-18	Biogal Gyogyszergyar Rt	Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
US6777552B2 (en)	2001-08-16	2004-08-17	Teva Pharmaceutical Industries, Ltd.	Processes for preparing calcium salt forms of statins
KR100877165B1 (ko)	2000-11-16	2009-01-07	테바 파마슈티컬 인더스트리즈 리미티드	수산화 칼슘을 이용한[Ｒ(Ｒ,Ｒ)]-2-(4-플루오로페닐)-β,δ-디하이드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카보닐]-1Ｈ-피롤-1-헵탄산 에스테르의 가수분해
IL156055A0 (en)	2000-11-30	2003-12-23	Teva Pharma	Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
NL1017548C2 (nl)	2001-03-09	2002-09-10	Synthon Bv	Een lactonisatie proces.
IN190564B (no)	2001-04-11	2003-08-09	Cadila Heathcare Ltd
TR200400600T3 (tr)	2001-06-06	2004-06-21	Bristol-Myers Squibb Company	Kiral diol sülfonlar ve dihidroksi asit HMG COA redüktaz inhibitörlerinin hazırlanmsı için işlem
AU2002318041B2 (en) *	2001-07-13	2008-01-03	Astrazeneca Uk Limited	Preparation of aminopyrimidine compounds
AU2002324715B2 (en)	2001-08-16	2009-03-12	Teva Pharmaceutical Industries Ltd.	Processes for preparing calcium salt forms of statins
CN1545502A (zh)	2001-08-22	2004-11-10	��⻯ѧƷ�ع��޹�˾	吲哚衍生物的制备方法
EP1465667A4 (en)	2001-09-24	2007-06-27	Merck & Co Inc	SCREENING AND SELECTION PROCEDURE FOR STATIN COMBINATIONS
EP1323717A1 (en)	2001-12-27	2003-07-02	Dsm N.V.	Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
KR100511533B1 (ko)	2002-04-09	2005-08-31	임광민	키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
EP1585736A2 (en)	2002-05-21	2005-10-19	Ranbaxy Laboratories, Ltd.	Process for the preparation of rosuvastatin
EP1375493A1 (en)	2002-06-17	2004-01-02	Dsm N.V.	Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) *	2002-08-13	2002-09-18	Astrazeneca Ab	Chemical process
ATE501126T1 (de)	2002-12-10	2011-03-15	Ranbaxy Lab Ltd	Verfahren zur herstellung von rosuvastatin
MXPA05006425A (es)	2002-12-16	2005-08-19	Astrazeneka Uk Ltd	Procedimiento para la preparacion de compuestos de pirimidina.
EP1615884B1 (en)	2003-04-11	2016-06-29	LEK Pharmaceuticals d.d.	Process for the preparation of amorphous calcium salt of atorvastatin
WO2004103977A2 (en)	2003-05-21	2004-12-02	Ciba Specialty Chemicals Holding Inc.	Process for the preparation of pyrimidine derivatives
GB0312896D0 (en)	2003-06-05	2003-07-09	Astrazeneca Ab	Chemical process
WO2005005384A1 (en)	2003-07-15	2005-01-20	Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S.	Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
EP1562912A2 (en)	2003-08-28	2005-08-17	Teva Pharmaceutical Industries Limited	Process for preparation of rosuvastatin calcium
UY28501A1 (es) *	2003-09-10	2005-04-29	Astrazeneca Uk Ltd	Compuestos químicos
GB0321827D0 (en)	2003-09-18	2003-10-15	Astrazeneca Uk Ltd	Chemical compounds
GB0322552D0 (en)	2003-09-26	2003-10-29	Astrazeneca Uk Ltd	Therapeutic treatment
WO2005040134A1 (en)	2003-10-22	2005-05-06	Ranbaxy Laboratories Limited	Process for the preparation of amorphous rosuvastatin calcium
GB0324791D0 (en) *	2003-10-24	2003-11-26	Astrazeneca Ab	Chemical process
DE10352659B4 (de)	2003-11-11	2007-09-13	Ratiopharm Gmbh	Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren
TW200526596A (en)	2003-11-24	2005-08-16	Teva Pharma	Crystalline ammonium salts of rosuvastatin
WO2005077916A1 (en)	2004-01-19	2005-08-25	Ranbaxy Laboratories Limited	Salts of hmg-coa reductase inhibitors and use thereof
ATE507209T1 (de)	2003-12-02	2011-05-15	Teva Pharma	Referenzstandard zur charakterisierung von rosuvastatin
WO2005054207A1 (en)	2003-12-04	2005-06-16	Glenmark Pharmaceuticals Limited	Process for the preparation of pyrimidine derivatives
CA2550742A1 (en)	2003-12-24	2005-07-14	Teva Pharmaceutical Industries Ltd.	Process for preparation of statins with high syn to anti ratio
CZ200486A3 (cs)	2004-01-16	2005-08-17	Zentiva, A.S.	Způsob výroby hemivápenaté soli (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenové kyseliny
WO2005077917A1 (en)	2004-01-19	2005-08-25	Ranbaxy Laboratories Limited	Amorphous salts of rosuvastatin
US7241800B2 (en)	2004-03-17	2007-07-10	Mai De Ltd.	Anhydrous amorphous form of fluvastatin sodium
GB0406757D0 (en)	2004-03-26	2004-04-28	Avecia Ltd	Process and compounds
US7161004B2 (en)	2004-06-21	2007-01-09	Dr. Reddy's Laboratories Limited	Processes to produce intermediates for rosuvastatin
CA2573857A1 (en)	2004-07-13	2006-02-16	Teva Pharmaceutical Industries Ltd.	A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
EP1797046A2 (en)	2004-09-27	2007-06-20	Ranbaxy Laboratories Limited	Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
GB0428328D0 (en)	2004-12-24	2005-02-02	Astrazeneca Uk Ltd	Chemical process
EP1844021A1 (en)	2005-01-31	2007-10-17	Ciba Specialty Chemicals Holding Inc.	Crystalline forms of rosuvastatin calcium salt
CA2498978A1 (en)	2005-02-28	2006-08-28	Apotex Pharmachem Inc.	An improved process for the preparation of atorvastatin and intermediates
GB0514078D0 (en) *	2005-07-08	2005-08-17	Astrazeneca Uk Ltd	Chemical process
TW200831469A (en) *	2006-12-01	2008-08-01	Astrazeneca Uk Ltd	Chemical process

2003
- 2003-06-05 GB GBGB0312896.4A patent/GB0312896D0/en not_active Ceased
- 2003-10-24 GB GBGB0324793.9A patent/GB0324793D0/en not_active Ceased
2004
- 2004-05-24 TW TW093114667A patent/TWI341310B/zh not_active IP Right Cessation
- 2004-06-02 UY UY28341A patent/UY28341A1/es not_active Application Discontinuation
- 2004-06-03 KR KR1020057023329A patent/KR101099934B1/ko not_active Expired - Lifetime
- 2004-06-03 WO PCT/GB2004/002373 patent/WO2004108691A1/en active Application Filing
- 2004-06-03 CN CNB2004800154822A patent/CN100422157C/zh not_active Expired - Lifetime
- 2004-06-03 MX MXPA05013128A patent/MXPA05013128A/es active IP Right Grant
- 2004-06-03 EP EP04735910A patent/EP1633727B1/en not_active Expired - Lifetime
- 2004-06-03 RU RU2005138370/04A patent/RU2361864C2/ru active
- 2004-06-03 DE DE602004026576T patent/DE602004026576D1/de not_active Expired - Lifetime
- 2004-06-03 AT AT04735910T patent/ATE464297T1/de not_active IP Right Cessation
- 2004-06-03 AU AU2004245291A patent/AU2004245291B2/en not_active Expired
- 2004-06-03 BR BRPI0410922A patent/BRPI0410922B8/pt active IP Right Grant
- 2004-06-03 ES ES04735910T patent/ES2341858T3/es not_active Expired - Lifetime
- 2004-06-03 CA CA2527314A patent/CA2527314C/en not_active Expired - Fee Related
- 2004-06-03 NZ NZ543962A patent/NZ543962A/en not_active IP Right Cessation
- 2004-06-03 MY MYPI20042138A patent/MY140820A/en unknown
- 2004-06-03 JP JP2006508394A patent/JP4651615B2/ja not_active Expired - Lifetime
- 2004-06-03 US US10/558,390 patent/US8063213B2/en active Active
- 2004-06-04 AR ARP040101944A patent/AR044773A1/es unknown
- 2004-07-14 SA SA04250223A patent/SA04250223B1/ar unknown
2005
- 2005-11-21 IL IL172075A patent/IL172075A/en active IP Right Grant
- 2005-12-02 CO CO05122683A patent/CO5640116A2/es unknown
- 2005-12-05 NO NO20055730A patent/NO332971B1/no not_active IP Right Cessation
2006
- 2006-01-02 IS IS8217A patent/IS2751B/is unknown

Also Published As

Publication number	Publication date
CA2527314A1 (en)	2004-12-16
GB0312896D0 (en)	2003-07-09
MY140820A (en)	2010-01-29
MXPA05013128A (es)	2006-03-16
WO2004108691A1 (en)	2004-12-16
EP1633727A1 (en)	2006-03-15
US8063213B2 (en)	2011-11-22
IS8217A (is)	2006-01-02
AU2004245291A1 (en)	2004-12-16
RU2361864C2 (ru)	2009-07-20
NO332971B1 (no)	2013-02-11
NZ543962A (en)	2008-09-26
BRPI0410922A (pt)	2006-06-27
NO20055730L (no)	2005-12-27
CN100422157C (zh)	2008-10-01
TW200510337A (en)	2005-03-16
CN1798741A (zh)	2006-07-05
IL172075A (en)	2011-06-30
IS2751B (is)	2011-09-15
AR044773A1 (es)	2005-10-05
BRPI0410922B1 (pt)	2016-02-23
ATE464297T1 (de)	2010-04-15
UY28341A1 (es)	2005-01-31
US20080221323A1 (en)	2008-09-11
JP4651615B2 (ja)	2011-03-16
BRPI0410922B8 (pt)	2021-05-25
DE602004026576D1 (de)	2010-05-27
KR20060017848A (ko)	2006-02-27
CO5640116A2 (es)	2006-05-31
HK1087405A1 (en)	2006-10-13
CA2527314C (en)	2012-02-21
GB0324793D0 (en)	2003-11-26
TWI341310B (en)	2011-05-01
AU2004245291B2 (en)	2008-02-14
SA04250223B1 (ar)	2008-12-23
JP2006526602A (ja)	2006-11-24
RU2005138370A (ru)	2006-07-10
ES2341858T3 (es)	2010-06-29
EP1633727B1 (en)	2010-04-14
KR101099934B1 (ko)	2011-12-28

Publication	Publication Date	Title
NO20055730D0 (no)	2005-12-05	Forbedret produksjon av rosuvastatin kalsiumsalt
IS7728A (is)	2005-03-08	Aðferð til að framleiða kalsíumsalt rósuvastatíns
CY2015015I1 (el)	2020-05-29	Παραγωγη τιακουμυκινης
NO20041082L (no)	2004-03-15	Fremgangsmater for fremstilling av kalsiumsaltformer av statiner
IL173858A0 (en)	2006-07-05	Process for preparation of rosuvastatin calcium
MA28802B1 (fr)	2007-08-01	Utilisations therapeutiques d'inhibiteurs de rtp801
NO20054684D0 (no)	2005-10-12	Merking av masse
NO20043660L (no)	2004-10-12	Salter av valsartan
ATE428701T1 (de)	2009-05-15	Kristalline form von bisä(e)-7-ä4-(4-fluorphenyl)-6-isopropyl-2-
NO20050118D0 (no)	2005-01-10	Substituerte fenylsulfonamidinhibitorer av beta-amyolid produksjon
NO20052474D0 (no)	2005-05-23	Amort form av esomeprazolsalter
DE602005027308D1 (de)	2011-05-19	Stabile salze von olanzapin
IS8399A (is)	2006-04-05	Form fjölgervings 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólíns
DE502004011575D1 (de)	2010-10-07	Verwendung von Dioldimerfettsäureestern
HRP20150163T1 (xx)	2015-03-27	Postupak za proizvodnju n-supstituiranih 2-cijanopirolidina
IS8321A (is)	2006-02-22	Stöðug afbrigði tegaseródvetnismaleats
PL371629A1 (pl)	2005-06-27	Sposób wytwarzania kombrestatyn
EP1686864A4 (en)	2009-09-23	CALCIUM FOOD SUPPLEMENT
NO20044050L (no)	2004-09-24	Fremgangsmate for syntese av chirale N-aryl-piperaziner
DE60323456D1 (de)	2008-10-23	Herstellung von Nanopartikeln
NO20034597D0 (no)	2003-10-14	Fremgangsmåte for fremstilling av cantaxantin
ATE499348T1 (de)	2011-03-15	Stabiler polymorph von bifeprunoxmesilat
IS7477A (is)	2004-09-30	Aðferð við framleiðslu sýrusalts af gemifloxasíni
FR2864109B1 (fr)	2006-07-21	Croissance organisee de nano-structures
NO20030784D0 (no)	2003-02-19	Forhindring av inkrustasjoner av fosfatholdige dobbeltsalter

Legal Events

Date	Code	Title	Description
2017-01-30	MM1K	Lapsed by not paying the annual fees